Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity

• मुख्य लेखकों: Katharina Schütz (लेखक), Sophia Theres Pallenberg (लेखक), Julia Kontsendorn (लेखक), David DeLuca (लेखक), Cinja Sukdolak (लेखक), Rebecca Minso (लेखक), Tina Büttner (लेखक), Martin Wetzke (लेखक), Christian Dopfer (लेखक), Annette Sauer-Heilborn (लेखक), Felix C. Ringshausen (लेखक), Sibylle Junge (लेखक), Burkhard Tümmler (लेखक), Gesine Hansen (लेखक), Anna-Maria Dittrich (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2023-07-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Introduction: Triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) was introduced in August 2020 in Germany for people with CF (pwCF) ≥12 years (yrs.) of age and in June 2021 for pwCF ≥6 yrs of age. In this single...